Literature DB >> 20361986

5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease.

Marcus C Ferguson1, Tultul Nayyar, Ariel Y Deutch, Twum A Ansah.   

Abstract

Clinical observations have suggested that ritanserin, a 5-HT(2A/C) receptor antagonist may reduce motor deficits in persons with Parkinson's Disease (PD). To better understand the potential antiparkinsonian actions of ritanserin, we compared the effects of ritanserin with the selective 5-HT(2A) receptor antagonist M100907 and the selective 5-HT(2C) receptor antagonist SB 206553 on motor impairments in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). MPTP-treated mice exhibited decreased performance on the beam-walking apparatus. These motor deficits were reversed by acute treatment with L-3,4-dihydroxyphenylalanine (levodopa). Both the mixed 5-HT(2A/C) antagonist ritanserin and the selective 5-HT(2A) antagonist M100907 improved motor performance on the beam-walking apparatus. In contrast, SB 206553 was ineffective in improving the motor deficits in MPTP-treated mice. These data suggest that 5-HT(2A) receptor antagonists may represent a novel approach to ameliorate motor symptoms of Parkinson's disease. Published by Elsevier Ltd.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20361986      PMCID： PMC2878885          DOI： 10.1016/j.neuropharm.2010.03.013

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN： 0028-3908            Impact factor:   5.250


  73 in total

1.  MPTP-induced hypoactivity in mice: reversal by L-dopa.

Authors:  A Fredriksson; A Plaznik; E Sundström; G Jonsson; T Archer
Journal:  Pharmacol Toxicol       Date:  1990-10

2.  Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin.

Authors:  C H Miller; W W Fleischhacker; H Ehrmann; J M Kane
Journal:  Psychopharmacol Bull       Date:  1990

3.  5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.

Authors:  G Bersani; A Grispini; S Marini; A Pasini; M Valducci; N Ciani
Journal:  Clin Neuropharmacol       Date:  1990-12       Impact factor: 1.592

4.  Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by L-dopa.

Authors:  K Nishi; T Kondo; H Narabayashi
Journal:  Neurosci Lett       Date:  1991-02-25       Impact factor: 3.046

5.  Serotonin2/1C receptor activation causes a localized expression of the immediate-early gene c-fos in rat brain: evidence for involvement of dorsal raphe nucleus projection fibres.

Authors:  R A Leslie; J M Moorman; A Coulson; D G Grahame-Smith
Journal:  Neuroscience       Date:  1993-03       Impact factor: 3.590

6.  Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell.

Authors:  A Y Deutch; D S Cameron
Journal:  Neuroscience       Date:  1992       Impact factor: 3.590

7.  Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.

Authors:  J H Kehne; B M Baron; A A Carr; S F Chaney; J Elands; D J Feldman; R A Frank; P L van Giersbergen; T C McCloskey; M P Johnson; D R McCarty; M Poirot; Y Senyah; B W Siegel; C Widmaier
Journal:  J Pharmacol Exp Ther       Date:  1996-05       Impact factor: 4.030

8.  Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors.

Authors:  M Pompeiano; J M Palacios; G Mengod
Journal:  Brain Res Mol Brain Res       Date:  1994-04

9.  Effect of ritanserin, a highly selective 5-HT2 receptor antagonist, on Parkinson's disease.

Authors:  J Henderson; C Yiannikas; J S Graham
Journal:  Clin Exp Neurol       Date:  1992

10.  The effect of ritanserin on treatment-resistant neuroleptic induced akathisia: case reports.

Authors:  C H Miller; M Hummer; R Pycha; W W Fleischhacker
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1992-03       Impact factor: 5.067
View more
  12 in total

1.  FABP3 protein promotes α-synuclein oligomerization associated with 1-methyl-1,2,3,6-tetrahydropiridine-induced neurotoxicity.

Authors:  Norifumi Shioda; Yasushi Yabuki; Yuka Kobayashi; Misaki Onozato; Yuji Owada; Kohji Fukunaga
Journal:  J Biol Chem       Date:  2014-05-22       Impact factor: 5.157

2.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

Review 3.  Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.

Authors:  Kathryn Lanza; Christopher Bishop
Journal:  J Neural Transm (Vienna)       Date:  2018-01-05       Impact factor: 3.575

Review 4.  Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Mol Neurobiol       Date:  2012-01-06       Impact factor: 5.590

5.  Effects of 5-hydroxytryptamine 2C receptor agonist MK212 and 2A receptor antagonist MDL100907 on maternal behavior in postpartum female rats.

Authors:  Weihai Chen; Qi Zhang; Wenxin Su; Haorong Zhang; Yu Yang; Jing Qiao; Nan Sui; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2013-12-07       Impact factor: 3.533

6.  Chronic methamphetamine exposure produces a delayed, long-lasting memory deficit.

Authors:  Ashley North; Jarod Swant; Michael F Salvatore; Joyonna Gamble-George; Petra Prins; Brittany Butler; Mukul K Mittal; Rebecca Heltsley; John T Clark; Habibeh Khoshbouei
Journal:  Synapse       Date:  2013-02-08       Impact factor: 2.562

7.  Prenatal exposure to methanol as a dopamine system sensitization model in C57BL/6J mice.

Authors:  Veronica R Mackey; Gladson Muthian; Marquitta Smith; Jennifer King; Clivel G Charlton
Journal:  Life Sci       Date:  2012-09-20       Impact factor: 5.037

8.  Reverse microdialysis of a 5-HT2A receptor antagonist alters extracellular glutamate levels in the striatum of the MPTP mouse model of Parkinson's disease.

Authors:  Marcus C Ferguson; Tultul Nayyar; Twum A Ansah
Journal:  Neurochem Int       Date:  2014-04-04       Impact factor: 3.921

9.  The 5-HT(2A) Receptor Antagonist M100907 Produces Antiparkinsonian Effects and Decreases Striatal Glutamate.

Authors:  Twum A Ansah; Marcus C Ferguson; Tultul Nayyar
Journal:  Front Syst Neurosci       Date:  2011-06-14

10.  Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson's disease.

Authors:  Naoto Kadoguchi; Shinji Okabe; Yukio Yamamura; Misaki Shono; Tatsuya Fukano; Akie Tanabe; Hironori Yokoyama; Jiro Kasahara
Journal:  BMC Neurosci       Date:  2014-06-25       Impact factor: 3.288
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.